Influence of vehicles on the in vitro percutaneous absorption of piroxicam to optimise the formulation of patch tests in dermatology

Drug Development Research

Volumn 58, Issue 3, 2003, Pages 283-290

  D'Arpino, Stéphanie ^a,b   Corbrion Archer, Valérie ^a   Marty, Jean Paul ^b   Lantieri, Laurent ^a   Vincent, Claire Marie ^b   Astier, Alain ^a   Paul, Muriel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Franz type diffusion cell; In vitro percutaneous absorption; Patch tests; Piroxicam; Vehicles

Indexed keywords

DRUG VEHICLE; MACROGOL 400; PETROLATUM; PIROXICAM; PROPYLENE GLYCOL; TRANSCUTOL P; UNCLASSIFIED DRUG;

ABDOMEN; ARTICLE; CONTROLLED STUDY; DERMIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; EPIDERMIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PATCH TEST; SKIN ABSORPTION; THERMODYNAMICS;

EID: 0037541497     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10164     Document Type: Article

References (23)

1. Abe T. 1982. Piroxicam as a new adjunct for the treatment of rheumatoid arthritis. Am J Med 79:39-44.
2. Alanko K, Stubb S, Reitamo D. 1981. Topical provocation of fixed drug eruption. Br J Dermatol 116:561-567.
3. Babar A, Solanki UD, Cutie AJ, Plakogiannis F. 1990. Piroxicam release from dermatological bases: in-vitro studies using cellulose membrane and hairless mouse skin. Drug Dev Ind Pharm 16:523-540.
4. Bach M, Lippold BC. 1998. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 46:1-13.
5. Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit MA, Ehlinger A, Noirez V, Faure GC, Schmutz JL, Bebe MC. 1998. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 139:49-58.
6. Carrabba M, Paresce E, Angelini M, Galanti, Marini MG, Cigarini P. 1995. A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Curr Med Res Opin 13:343-355.
7. Csoka G, Racz I, Marton S, Balogh E, Farkas E. 1999. Formulation of novel soft-patch type gel systems containing non-steroidal anti-inflammatory drugs. Pharm Ind 61:88-91.
8. Gerber D. 1987. Adverse reactions of piroxicam. Drug Intell Clin Pharm 21:707-710.
9. Guillaume JC, Roujeau JC, Chevais M, Albengres E, Revuz J, Touraine R. 1985. Syndrome de Lyell et ectodermose pluriorificielle au cours de traitements par les oxicams: 11 observations. Ann Dermatol Venereol 112:807-812.
10. Harrison JE, Watkinson AC, Green DM, Hadgraft J, Brain K. 1996. The relative effect of Azone® and Transeutol® on permeant diffusivity and solubility in human stratum corneum. Pharm Res 13:542-546.
11. Katoh N, Kagawa K, Yasuno H. 1995. Piroxicam induced Stevens-Johnson syndrome. J Dermatol 22:677-680.
12. Kim YH, Ghanem AH, Higuchi WI. 1992. Model studies of epidermal permeability. Semin Dermatol 11:145-156.
13. Milpied-Homsi B. 1995. Dermites de contact aux anti-inflammatoires non stéroïdiens topiques. GERDA 1:89-101.
14. Okamoto H, Muta K, Hashida M, Sezaki. 1990. Percutaneous penetration of acyclovir through excised hairless mouse and rat skin: effect of vehicle and percutaneous penetration enhancer. Pharm Res 7:64-68.
15. Okuyama H, Ikeda Y, Kasai S, Imamori K, Takayama K, Nagai T. 1999. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. Int J Pharm 186:141-148.
16. Phelip X. 1984. La toléranee du Feldèner® (piroxicam) - bilan de trois études coopératives concernant 48 353 observations. Gaz Med 91:93-96.
17. Pitts NE. 1982. Efficacy and safety of piroxicam. Am J Med 72:77-87.
18. Ritschel WA, Panchagnula R, Stemmer K, Ashraf M. 1991. Development of an intracutaneous depot for drugs. Skin Pharmacol 4:235-245.
19. Santoyo S, Arellano A, Ygartua P, Martin C. 1996. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Pharm Acta Helv 71:141-146.
20. Skelly JP, Shah VP, Maibach HI, Guy RH, Wester RC, Flynn G, Yacobi A. 1987. Report of the Workshop on Principles and Practices of In Vitro Percutaneous Penetration Studies: relevance to bioavailability and bioequivalence. Pharm Res 4:265-267.
21. Stern RS, Bigby. 1984. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. JAMA 252:1433-1437.
22. Twomey TM, Bartolucci SR, Hobbs DC. 1980. Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183:104-108.
23. Vasconcelos C, Magina S, Quirino P, Barros MA, Mesquita-Guimaraes J. 1997. Cutaneous drug reactions to piroxicam. Contact Dermatitis 39:145.